Literature DB >> 12372277

Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders.

Christopher A Ross1.   

Abstract

The mechanisms of neurodegeneration in the CAG repeat polyglutamine diseases, including Spinal and Bulbar Muscular Atrophy (SBMA), Huntington's disease (HD), DentatoRubral and PallidoLuysian Atrophy (DRPLA), and Spino-Cerebellar Ataxia (SCA), have been controversial. Issues have included the role of polyglutamine aggregation and possible amyloid formation, localization in the cell nucleus, and possible proteolytic processing. Proposed mechanisms have included activation of caspases or other triggers of apoptosis, mitochondrial or metabolic toxicity, and interference with gene transcription. Recent studies using transgenic mouse and Drosophila models have helped resolve some of these issues and raise hopes for development of therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12372277     DOI: 10.1016/s0896-6273(02)00872-3

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  146 in total

1.  Disrupted GABAAR trafficking and synaptic inhibition in a mouse model of Huntington's disease.

Authors:  Eunice Y Yuen; Jing Wei; Ping Zhong; Zhen Yan
Journal:  Neurobiol Dis       Date:  2012-02-28       Impact factor: 5.996

2.  A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila.

Authors:  Barbara L Apostol; Alexsey Kazantsev; Simona Raffioni; Katalin Illes; Judit Pallos; Laszlo Bodai; Natalia Slepko; James E Bear; Frank B Gertler; Steven Hersch; David E Housman; J Lawrence Marsh; Leslie Michels Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-01       Impact factor: 11.205

3.  Polyglutamine fibrillogenesis: the pathway unfolds.

Authors:  Christopher A Ross; Michelle A Poirier; Erich E Wanker; Mario Amzel
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-30       Impact factor: 11.205

4.  Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington's disease.

Authors:  Wyan-Ching Mimi Lee; Motojiro Yoshihara; J Troy Littleton
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-20       Impact factor: 11.205

5.  Human cytomegalovirus UL97 kinase prevents the deposition of mutant protein aggregates in cellular models of Huntington's disease and ataxia.

Authors:  Cristy Tower; Lianwu Fu; Rachel Gill; Mark Prichard; Mathieu Lesort; Elizabeth Sztul
Journal:  Neurobiol Dis       Date:  2010-08-20       Impact factor: 5.996

6.  An unstructured region is required by GAV homologue for the fibrillization of host proteins.

Authors:  Li-Na Ji; Hai-Ning Du; Feng Zhang; Hong-Tao Li; Xiao-Ying Luo; Jun Hu; Hong-Yu Hu
Journal:  Protein J       Date:  2005-05       Impact factor: 2.371

Review 7.  Huntington's disease genetics.

Authors:  Richard H Myers
Journal:  NeuroRx       Date:  2004-04

8.  Dysregulation of mitochondrial calcium signaling and superoxide flashes cause mitochondrial genomic DNA damage in Huntington disease.

Authors:  Jiu-Qiang Wang; Qian Chen; Xianhua Wang; Qiao-Chu Wang; Yun Wang; He-Ping Cheng; Caixia Guo; Qinmiao Sun; Quan Chen; Tie-Shan Tang
Journal:  J Biol Chem       Date:  2012-12-17       Impact factor: 5.157

9.  Huntington's disease protein contributes to RNA-mediated gene silencing through association with Argonaute and P bodies.

Authors:  Jeffrey N Savas; Anthony Makusky; Søren Ottosen; David Baillat; Florian Then; Dimitri Krainc; Ramin Shiekhattar; Sanford P Markey; Naoko Tanese
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-31       Impact factor: 11.205

10.  Using zebrafish to assess the impact of drugs on neural development and function.

Authors:  Su Guo
Journal:  Expert Opin Drug Discov       Date:  2009-07-01       Impact factor: 6.098

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.